regulatory
confidence high
sentiment positive
materiality 0.50
GT Biopharma regains Nasdaq $1.00 minimum bid price compliance as of September 22, 2026
GT Biopharma, Inc.
- Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
- Common stock (GTBP) closed above $1.00 per share for at least ten consecutive business days, satisfying Nasdaq's standard for regaining compliance.
- Deficiency began with a November 20, 2025 Nasdaq staff letter citing 30 consecutive business days below $1.00; Nasdaq granted a 180-day extension on May 20, 2026 running to November 16, 2026.
- The notice removes the pending delisting risk that had been outstanding for roughly ten months; no capital raise, reverse split, or other remedial transaction is disclosed.